Immunogenicity of vaccine encoding spike protein against Middle East respiratory syndrome coronavirus in mammalian model.

Abo sherif, Mohamed Eid; Abo shama, Noura Mahrous; Hussein, Sara M; El-Desouky, Mohamed Aly; Hanna, Demiana Helmy; Ali, Mohamed Ahmed

doi:10.21608/ejchem.2024.276701.9459

	Immunogenicity of vaccine encoding spike protein against Middle East respiratory syndrome coronavirus in mammalian model.
Egyptian Journal of Chemistry
Articles in Press, Accepted Manuscript, Available Online from 28 April 2024
Document Type: Original Article
DOI: 10.21608/ejchem.2024.276701.9459
View on SCiNiTO
Authors
Mohamed Eid Abo sherif¹; Noura Mahrous Abo shama²; Sara M Hussein³; Mohamed Aly El-Desouky ⁴; Demiana Helmy Hanna ⁵; Mohamed Ahmed Ali ⁶
¹Egyptian Army
²Eva Pharmaceutical
³Center of Scientific Excellence for Virus Research,National Research Centre
⁴Biochemistry Department, Faculty of Science, Cairo University, Giza 12613, Egypt
⁵Department of Biochemistry,Faculty of Science,Cairo University
⁶El Bohouth St
Abstract
Abstract The Middle East respiratory syndrome coronavirus (MERS-CoV) represents a major threat to human health worldwide. No licensed MERS-CoV vaccines or therapeutics were developed. So, the aim of the current study is the generation and immunological evaluation of DNA vaccine candidate against MERS-CoV. The spike gene was selected to generate the DNA vaccine, which encodes the spike protein of coronaviruses that plays a pivotal role in viral entry into host cells and serves as a primary target for host immune responses. Moreover, the antibody responses post-immunization with spike-DNA fragment and inactivated coronaviruses vaccines was explored, using a microneutralization assay with severe acute respiratory syndrome (SARS-CoV-2), and the log2 antibody titers at different time points (0, 2, 4, 6, and 8 weeks) post-vaccination was measured. The inactivated MERS-CoV and pCDNA3.1-S-MERS-CoV vaccines maintained steady log2 antibody titers, showing no specific response to SARS-CoV-2 in the control group (PBS). Microneutralization against MERS-CoV showed no significant antibody titers for Inactivated SARS-CoV-2, suggesting no cross-reactivity. Sustained antibody titers for Inactivated MERS-CoV indicate vaccine-induced stability. This study sheds light on antibody responses induced by these vaccines against MERS-CoV. These insights are crucial for optimizing vaccine strategies, particularly in the context of the evolving MERS-CoV pandemic.
Keywords
Vaccine; spike; MERS-CoV; SARS-CoV-2; antibodies


Statistics Article View: 47